author-photo

Jonathon P. Orme

AstraZeneca

7

Papers

1717

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

2014 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (1184)
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

2014 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (327)
Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

2013 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (146)
Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.

2013 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (18)
EGFR-K IN COMPLEX WITH N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxy-phenyl] Prop-2-enamide

2013
Show All
- Source
- Cite
- Save
Citations (0)
Protein-Ligand Crystal Structures Can Guide the Design of Selective Inhibitors of the FGFR Tyrosine Kinase.

2012 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (36)